<DOC>
	<DOCNO>NCT00062205</DOCNO>
	<brief_summary>RATIONALE : Imatinib mesylate may stop growth tumor cell block enzymes necessary tumor cell growth . PURPOSE : This phase II trial study well imatinib mesylate work treat patient recurrent Ewing 's family tumor desmoplastic small round-cell tumor .</brief_summary>
	<brief_title>Imatinib Mesylate Treating Patients With Recurrent Ewing 's Family Tumors Desmoplastic Small Round-Cell Tumor</brief_title>
	<detailed_description>OBJECTIVES : - Determine effectiveness imatinib mesylate patient recurrent Ewing 's family tumor desmoplastic small round-cell tumor . - Determine toxic effect drug patient . - Determine duration disease-free overall survival patient treated drug . OUTLINE : This open-label study . Patients receive oral imatinib mesylate twice daily day 1-28 . Courses repeat every 28 day . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Ewing 's family tumor OR desmoplastic small roundcell tumor Must immunohistochemical evidence expression great 2+/4+ either Kit ( CD117 ) plateletderived growth factor receptor b No symptomatic brain metastasis Asymptomatic brain metastasis allow provided patient concurrent anticonvulsant corticosteroids PATIENT CHARACTERISTICS : Age Over 16 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 9 g/dL Hepatic Bilirubin less 1.5 time upper limit normal ( ULN ) SGOT SGPT less 2.5 time ULN No chronic active hepatitis No cirrhosis No acute know chronic liver disease Renal Creatinine less 1.5 time ULN Cardiovascular No concurrent poorly control severe cardiovascular disease Pulmonary No concurrent poorly control severe pulmonary disease Other HIV negative No concurrent poorly control severe central nervous system disease No concurrent poorly control severe nonmalignant disease PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy At least 3 week since prior chemotherapy Endocrine therapy See Disease Characteristics Radiotherapy At least 3 week since prior radiotherapy Surgery More 2 week since prior major surgery Other More 28 day since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>